|
| Status |
Public on Jun 05, 2021 |
| Title |
Identification of altered cell signaling pathways in stable and progressive chronic lymphocytic leukemia |
| Organism |
Homo sapiens |
| Experiment type |
Expression profiling by high throughput sequencing
|
| Summary |
Chronic lymphocytic leukemia (CLL) is characterized by significant biological and clinical heterogeneity. This study was designed to explore CLL B-cells’ proteomic profile in order to identify biological processes affected at an early stage and during disease evolution as stable or progressive. Purified B cells from 11 untreated CLL patients were tested at two time points by liquid chromatography-tandem mass spectrometry. Patients included in the study evolved to either progressive (n=6) or stable disease (n=5). First, at an early stage of the disease (Binet stage A), based on the relative abundance levels of 389 differentially expressed proteins (DEP), samples were separated into stable and progressive clusters with the main differentiating factor being RNA splicing pathway. Next, in order to test how the DEPs affect RNA splicing, a RNA-Seq study was conducted for 4 Stable and 4 Progressive CLL patients, showing 4217 differentially spliced genes between the two clusters. Distinct longitudinal evolutions were observed with predominantly proteomic modifications in the stable CLL group and spliced genes in the progressive CLL group. Splicing events were shown to be 6 times more frequent in the progressive CLL group. The main aberrant biological processes controlled by DEP and spliced genes in the progressive group were cytoskeletal organization, Wnt/β-catenin signaling, mitochondrial and inositol phosphate metabolism with a downstream impact on CLL B-cell survival and migration. This study suggests that proteomic profiles at the early stage of CLL can discriminate progressive from stable disease and that RNA splicing dysregulation underlies CLL evolution, which opens new perspectives in terms of biomarkers and therapy.
|
| |
|
| Overall design |
Purified B cells from 8 untreated CLL patients were tested at two time points by RNA-Seq. Patients included in the study evolved to either progressive (n=4, samples tested at diagnosis in Binet A disease and at the time of progressive disease to Binet B/C) or stable disease for more than 5 years (n=4, samples tested at diagnosis and 3 years after diagnosis).
Longitudinal study of stable and progressive CLL.
|
| |
|
| Contributor(s) |
Bagacean C, Renaudineau Y |
| Citation missing |
Has this study been published? Please login to update or notify GEO. |
| |
| Submission date |
Jun 04, 2021 |
| Last update date |
Jun 07, 2021 |
| Contact name |
Cristina Bagacean |
| E-mail(s) |
cbagacean@gmail.com
|
| Phone |
0604148674
|
| Organization name |
UBO
|
| Street address |
2 Avenue Foch
|
| City |
Brest |
| ZIP/Postal code |
29200 |
| Country |
France |
| |
|
| Platforms (1) |
| GPL24676 |
Illumina NovaSeq 6000 (Homo sapiens) |
|
| Samples (16)
|
|
| Relations |
| BioProject |
PRJNA735097 |
| SRA |
SRP322666 |
Less...
More...